openPR Logo
Press release

ER+ Breast Cancer Pipeline Analysis - Clinical Trials, Patent, Designation and Collaboration

ER+ Breast Cancer Pipeline Analysis - Clinical Trials, Patent,

The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates in different stages of development.

Explore report sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample

Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER+ breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed drugs, and classical toxins.

The research finds that different companies have collaborated for the development of ER+ breast cancer. In January 2016, Radius Health, Inc. entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer.

Browse Report at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis

Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., and others.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ER+ Breast Cancer Pipeline Analysis - Clinical Trials, Patent, Designation and Collaboration here

News-ID: 1209114 • Views:

More Releases from P&S Intelligence - Pharmaceuticals

Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Download report sample at: http://bit.ly/2eqiPu5 **Various collaborations for CDK inhibitors drug development Eli Lilly
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials and Developments
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development. As per the findings of the research, most of the drug candidates are being developed to be administered by oral route. Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent and Collaborations
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.

All 5 Releases


More Releases for ER+

ER+/HER2- Breast Cancer Market Insights and Future Outlook
Introduction Estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer is the most common molecular subtype of breast cancer, accounting for nearly 70% of all breast cancer diagnoses worldwide. This classification is defined by tumors that express estrogen receptors (ER) but lack human epidermal growth factor receptor 2 (HER2) amplification. The subtype's dominance in global oncology has positioned it as the central focus for therapeutic innovation, guidelines development, and precision medicine strategies. Historically managed with
Er YAG Laser Market Outlook and Future Projections for 2030
An Er:YAG laser (erbium-doped yttrium aluminum garnet) is a type of solid-state laser commonly used in medical and cosmetic procedures. It emits light at a wavelength of 2940 nm, which is highly absorbed by water, making it effective for precise tissue ablation and resurfacing. This laser is popular in dermatology and dentistry for its ability to gently remove layers of skin or tissue with minimal thermal damage and quick healing. The
Optical Brightener ER-I and ER-II Market Size Unveiled: Trends and Projections
The global Optical Brightener ER-I and ER-II market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Optical Brightener ER-I and ER-II market. For instance, the market dynamics section digs deep into the drivers, restraints,
Optical Brightener ER-I and ER-II Market by Key Players,Competitive landscape an …
LOS ANGELES, United States: The global Optical Brightener ER-I and ER-II market is analyzed in quite some detail in the report with a strong focus on the competitive landscape, segmentation, market dynamics, and regional market expansion. The report includes a thorough assessment of the business of key players operating in the global Optical Brightener ER-I and ER-II market. With deeper qualitative and quantitative analysis of the global Optical Brightener ER-I and
Optical Brightener ER-I and ER-II Market Trends, Regional Overview, Leading Comp …
LOS ANGELES, United States: The global Optical Brightener ER-I and ER-II market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Optical Brightener ER-I and ER-II market. For instance, the market dynamics section digs deep
ER Wagner adding 600-ton Servo Punch Press
Milwaukee-based ER Wagner announced it will have a new 600-ton Servo Punch Press available for production in late 2017, greatly increasing ER Wagner’s metal stamping capabilities. The Nidec Minster Corporation machine, which will be a part of ER Wagner’s new 157,000-square-foot corporate headquarters and state of the art manufacturing facility currently under construction in the Village of Menomonee Falls, Wis., is latest technology in metal stamping, giving the company the ability